Exactech, Inc. (NASDAQ:EXAC) has been given a consensus recommendation of “Hold” by the six research firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and four have given a hold recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $42.00.
Several equities analysts have weighed in on the stock. Robert W. Baird set a $34.00 price objective on shares of Exactech and gave the stock a “buy” rating in a research report on Sunday, October 15th. Zacks Investment Research cut shares of Exactech from a “hold” rating to a “sell” rating in a research report on Wednesday, October 25th. Gabelli cut shares of Exactech from a “buy” rating to a “hold” rating in a research report on Tuesday, October 24th. BidaskClub cut shares of Exactech from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. Finally, Sidoti cut shares of Exactech from a “buy” rating to a “neutral” rating in a research report on Monday, October 23rd.
ILLEGAL ACTIVITY NOTICE: “Analysts Set Exactech, Inc. (EXAC) Price Target at $42.00” was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.com-unik.info/2017/10/30/analysts-set-exactech-inc-exac-price-target-at-42-00.html.
Shares of Exactech (EXAC) traded down 0.36% on Wednesday, hitting $41.70. The company’s stock had a trading volume of 592,539 shares. The company has a market cap of $598.31 million, a price-to-earnings ratio of 801.92 and a beta of 1.01. The stock’s 50 day moving average is $33.45 and its 200-day moving average is $30.67. Exactech has a 52 week low of $22.20 and a 52 week high of $42.55.
Exactech (NASDAQ:EXAC) last posted its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.33 earnings per share for the quarter, hitting the consensus estimate of $0.33. Exactech had a net margin of 7.25% and a return on equity of 7.96%. The firm had revenue of $67.30 million for the quarter, compared to analysts’ expectations of $67.75 million. During the same period in the previous year, the company posted $0.31 EPS. The company’s quarterly revenue was up 1.8% compared to the same quarter last year. On average, equities research analysts anticipate that Exactech will post $1.30 earnings per share for the current year.
In other Exactech news, Director Fern Watts sold 1,013 shares of Exactech stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $29.04, for a total transaction of $29,417.52. Following the completion of the sale, the director now owns 4,727 shares of the company’s stock, valued at approximately $137,272.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 28.30% of the company’s stock.
Several large investors have recently modified their holdings of the business. Dimensional Fund Advisors LP boosted its stake in shares of Exactech by 6.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 827,761 shares of the medical equipment provider’s stock valued at $24,668,000 after buying an additional 47,315 shares during the period. Gamco Investors INC. ET AL acquired a new stake in shares of Exactech during the 2nd quarter valued at $18,463,000. Vanguard Group Inc. boosted its stake in shares of Exactech by 1.6% during the 2nd quarter. Vanguard Group Inc. now owns 415,253 shares of the medical equipment provider’s stock valued at $12,375,000 after buying an additional 6,594 shares during the period. Thomson Horstmann & Bryant Inc. boosted its stake in shares of Exactech by 42.2% during the 2nd quarter. Thomson Horstmann & Bryant Inc. now owns 274,062 shares of the medical equipment provider’s stock valued at $8,167,000 after buying an additional 81,291 shares during the period. Finally, FMR LLC boosted its stake in shares of Exactech by 51.6% during the 2nd quarter. FMR LLC now owns 251,876 shares of the medical equipment provider’s stock valued at $7,506,000 after buying an additional 85,709 shares during the period. 65.04% of the stock is owned by institutional investors.
Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.
What are top analysts saying about Exactech Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Exactech Inc. and related companies.